Dutasteride has been proposed as an effective therapy for frontal fibrosing alopecia (FFA). We sought to describe the therapeutic response to dutasteride and the most effective dosage in FFA compared with other therapeutic options or no treatment. This was a retrospective observational study including patients with FFA with a minimum follow-up of 12 months. Therapeutic response was evaluated according to the stabilization of the hairline recession. A total of 224 patients (222 females) with a median follow-up of 24 months (range 12-108 months) were included. The stabilization rate for the frontal, right, and left temporal regions after 12 months was 62%, 64%, and 62% in the dutasteride group (n = 148), 60%, 35%, and 35% with other systemic therapies (n = 20), and 30%, 41%, and 38% without systemic treatment (n = 56; = .000, .006, and .006, respectively). Stabilization showed a statistically significant association with an increasing dose of dutasteride (88%, 91%, and 84% with a weekly treatment of 5 or 7 doses of 0.5 mg [n = 32], < .005). Dutasteride was well tolerated in all patients. Limitations included the observational and retrospective design. Oral dutasteride was the most effective therapy with a dose-dependent response for FFA in real clinical practice compared with other systemic therapies or no systemic treatment.

中文翻译：

---

度他雄胺在实际临床实践中对大量额部纤维化性脱发患者的疗效

度他雄胺已被提议作为额叶纤维性脱发（FFA）的有效治疗方法。我们试图描述度他雄胺的治疗反应，以及与其他治疗方案或不治疗相比，FFA 中最有效的剂量。这是一项回顾性观察研究，包括 FFA 患者，随访时间至少为 12 个月。根据发际线后退的稳定性来评估治疗反应。共纳入 224 名患者（222 名女性），中位随访时间为 24 个月（范围 12-108 个月）。 12 个月后，度他雄胺组（n = 148）额叶、右、左颞区的稳定率为 62%、64% 和 62%，其他全身治疗组为 60%、35% 和 35%（ n = 20），以及未进行全身治疗的 30%、41% 和 38%（n = 56；分别 = 0.000、0.006 和 0.006）。稳定性显示与度他雄胺剂量增加有统计学显着相关性（每周治疗 5 或 7 剂 0.5 mg，分别为 88%、91% 和 84% [n = 32]，< .005）。所有患者对度他雄胺的耐受性良好。局限性包括观察性和回顾性设计。在实际临床实践中，与其他全身治疗或无全身治疗相比，口服度他雄胺是最有效的治疗方法，对 FFA 具有剂量依赖性反应。